Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Depreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization Leases Long-Term Debt Repayments Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares Issued Shares Outstanding Shares Outstanding

Ratios

Contineum Therapeutics (CTNM) Preferred Shares Issued (2023)

Contineum Therapeutics' Preferred Shares Issued history spans 1 years, with the latest figure at $10.2 million for Q3 2023.

Quarterly Preferred Shares Issued changed N/A to $10.2 million in Q3 2023 from the year-ago period, while the trailing twelve-month figure was $10.2 million through Dec 2024, changed N/A year-over-year, with the annual reading at $60.1 million for FY2023, N/A changed from the prior year.
Preferred Shares Issued came in at $10.2 million for Q3 2023, down from $27.9 million in the prior quarter.
In the past five years, Preferred Shares Issued ranged from a high of $27.9 million in Q2 2023 to a low of $10.2 million in Q3 2023.